INDICATION: LONSURF is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan‑based chemotherapy, an anti‑VEGF biological therapy, and if RAS wild type, an anti‑EGFR therapy.
INDICATION: LONSURF is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan‑based chemotherapy, an anti‑VEGF biological therapy, and if RAS wild type, an anti‑EGFR therapy.
Resources
Counseling Tips

Taiho Oncology Patient Support

A one‑stop source for the customized support patients need

Scroll Down

Access support

Taiho Oncology Patient Support

We know getting patients access to LONSURF® (trifluridine and tipiracil) tablets is a critical step in their treatment. We strive to make this process as simple as possible with:

Access and reimbursement support

  • Benefit Verifications (BVs) to determine and report patients' insurance coverage for LONSURF
  • Prior authorization assistance to meet payer requirements
  • Claims appeals assistance if coverage is denied

Specialty pharmacy prescription coordination

  • Prescription triage
  • Coordination with the in-network specialty pharmacy, self‑dispensing practice, or hospital outpatient pharmacy
  • Communicating regularly with patients about their prescription status
Taiho Oncology Patient Support

Co-pay support

For patients who have difficulty affording their medicine, financial support programs are available.

Type of Patient Coverage
How We Can Help

Privately/commercially
insured patients

Taiho Oncology Patient Support Co‑pay Card

  • Reduces out‑of‑pocket costs for your eligible patients

Publicly/government-
insured patients

Referrals to nonprofit foundations for co‑pay or other financial assistance

  • Medicare or Medicaid patients may be referred to a co‑pay assistance foundation. We can help you apply for aid*

Patient Assistance Program

  • This program provides financial assistance for eligible patients who have insufficient insurance coverage for LONSURF, including Medicaid, Medicare, or any other public or private program, and who have insufficient financial resources to pay for their treatment. To apply, the patient will need to read, fill out, and sign page 3 of the Patient Enrollment Form. Income documentation and insurance information will be required
  • Taiho Oncology Patient Support may arrange for the patient to receive LONSURF at no cost based on assistance, financial, and medical criteria

Underinsured or uninsured
patients

Referrals to nonprofit foundations for co‑pay or other financial assistance

  • Medicare or Medicaid patients may be referred to a co‑pay assistance foundation. We can help you apply for aid*

Patient Assistance Program

  • This program provides financial assistance for eligible patients who have insufficient or no prescription insurance coverage for LONSURF, including Medicaid, Medicare, or any other public or private program, and who have insufficient financial resources to pay for their treatment. To apply, the patient will need to read, fill out, and sign page 3 of the Patient Enrollment Form. Income documentation and insurance information will be required
  • Taiho Oncology Patient Support may arrange for the patient to receive LONSURF at no cost based on assistance, financial, and medical criteria

To learn more, call the resource center at 1‑8‍4‍4‑T‍A‍I‍H‍O‑4‍U (1‑8‍4‍4‑8‍2‍4‑4‍6‍4‍8) or visit:

*Taiho Oncology does not influence or control the decisions of these co‑pay assistance foundations, but Taiho Oncology Patient Support can assist patients by making an appropriate referral based on a patient's diagnosis and by assisting with the application process. Each co‑pay assistance foundation has its own criteria for patient eligibility. We cannot guarantee financial assistance once a patient has been referred.

Video

Taiho Oncology is committed to partnering with you to help patients get the most out of therapy. To that end, Tim Whitten, Senior Vice President and Chief Operating Officer, introduces the Taiho Oncology Patient Support program—a resource center offering patients access, reimbursement and treatment support services.

Personalized nurse support

If selected on the Patient Enrollment Form, your patient will be paired with a Nurse Navigator who will be available to provide telephone support 24 hours a day, 7 days a week for LONSURF, including:

  • Treatment education
  • Medication support, including refill reminders
  • Addressing general inquiries about LONSURF such as what to expect on treatment, dosing, side effect management, etc.

How to enroll your patients

Ready


3 ways to enroll makes it convenient and easy for you

  1. Complete all applicable sections and pages of a printed Patient Enrollment Form, have the patient or patient representative and physician sign the form, and fax to Taiho Oncology Patient Support at 1‑8‍4‍4‑2‍8‍7‑2‍5‍5‍9.
  2. Fill out the Patient Enrollment Form on TaihoPatientSupport.com.
  3. Call 1‑8‍4‍4‑T‍A‍I‍H‍O‑4‍U (1‑8‍4‍4‑8‍2‍4‑4‍6‍4‍8) for help with enrollment.

Set


A Taiho Oncology Patient Support Reimbursement Specialist:

  • Contacts you to confirm receipt of the Patient Enrollment Form and next steps
  • Creates the patient's account and ensures completeness of information
  • Facilitates services selected on the Patient Enrollment Form
  • Is available to triage the patient's prescription and coordinate with the dispensing specialty pharmacy once LONSURF coverage has been verified
  • Coordinates follow‑up, reminders, and personalized nurse support upon request

Go!


What can the patient expect?

  1. Taiho Oncology Patient Support welcomes the patient to the program and explains his or her insurance benefits for LONSURF. The patient's Reimbursement Specialist confirms patient access to LONSURF via insurance coverage or assists patient in applying for financial assistance for LONSURF.
  2. The specialty pharmacy calls the patient to discuss payment and shipment, if applicable.
  3. The patient receives LONSURF from the specialty pharmacy, physician, or hospital and follows instructions for beginning treatment.

To enroll your patients, complete the Patient Enrollment form on TaihoPatientSupport.com

Or, call our Toll-free Resource Center at
1‑8‍4‍4‑T‍A‍I‍H‍O‑4‍U (1‑8‍4‍4‑8‍2‍4‑4‍6‍4‍8)

Monday through Friday, 8:00 AM to 8:00 PM ET
On-call Nurse Phone Support—24 hours a day, 7 days a week

Fax:
1‑8‍4‍4‑2‍8‍7‑2‍5‍5‍9

Important Safety Information +

WARNINGS AND PRECAUTIONS

Severe Myelosuppression: In Study 1, LONSURF caused severe and life‑threatening myelosuppression (Grade 3‑4) consisting of anemia (18%), neutropenia (38%), thrombocytopenia (5%), and febrile neutropenia (3.8%). One patient (0.2%) died due to neutropenic infection. In Study 1, 9.4% of LONSURF‑treated patients received granulocyte‑colony stimulating factors.

Obtain complete blood counts prior to and on day 15 of each cycle of LONSURF and more frequently as clinically indicated. Withhold LONSURF for febrile neutropenia, Grade 4 neutropenia, or platelets less than 50,000/mm3. Upon recovery, resume LONSURF at a reduced dose as clinically indicated.

Embryo‑Fetal Toxicity: LONSURF can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with LONSURF.

USE IN SPECIFIC POPULATIONS

Lactation: It is not known whether LONSURF or its metabolites are present in human milk. There are no data to assess the effects of LONSURF or its metabolites on the breast‑fed infant or the effects on milk production. Because of the potential for serious adverse reactions in breast‑fed infants, advise women not to breastfeed during treatment with LONSURF and for 1 day following the final dose.

Male Contraception: Because of the potential for genotoxicity, advise males with female partners of reproductive potential to use condoms during treatment with LONSURF and for at least 3 months after the final dose.

Geriatric Use: Patients 65 years of age or over who received LONSURF had a higher incidence of the following compared to patients younger than 65 years: Grade 3 or 4 neutropenia (48% vs 30%), Grade 3 anemia (26% vs 12%), and Grade 3 or 4 thrombocytopenia (9% vs 2%).

Hepatic Impairment: Patients with severe hepatic impairment (total bilirubin greater than 3 times ULN and any AST) were not studied. No adjustment to the starting dose of LONSURF is recommended for patients with mild hepatic impairment. Do not initiate LONSURF in patients with baseline moderate or severe (total bilirubin greater than 1.5 times ULN and any AST) hepatic impairment.

Renal Impairment: In Study 1, patients with moderate renal impairment (CLcr=30 to 59 mL/min, n=47) had a higher incidence (difference of at least 5%) of ≥Grade 3 adverse events, serious adverse events, and dose delays and reductions compared to patients with normal renal function (CLcr ≥90 mL/min, n=306) or patients with mild renal impairment (CLcr=60 to 89 mL/min, n=178).

Patients with moderate renal impairment may require dose modifications for increased toxicity. Patients with severe renal impairment were not studied.

ADVERSE REACTIONS

Most Common Adverse Drug Reactions in Patients Treated With LONSURF (≥5%): The most common adverse drug reactions in LONSURF‑treated patients vs placebo‑treated patients with refractory mCRC, respectively, were asthenia/fatigue (52% vs 35%), nausea (48% vs 24%), decreased appetite (39% vs 29%), diarrhea (32% vs 12%), vomiting (28% vs 14%), abdominal pain (21% vs 18%), pyrexia (19% vs 14%), stomatitis (8% vs 6%), dysgeusia (7% vs 2%), and alopecia (7% vs 1%).

Additional Important Adverse Drug Reactions: The following occurred more frequently in LONSURF‑treated patients compared to placebo: infections (27% vs 15%) and pulmonary emboli (2% vs 0%).

The most commonly reported infections which occurred more frequently in LONSURF‑treated patients were nasopharyngitis (4% vs 2%) and urinary tract infections (4% vs 2%).

Interstitial lung disease (0.2%), including fatalities, has been reported in clinical studies and clinical practice settings in Asia.

Laboratory Test Abnormalities in Patients Treated With LONSURF: Laboratory test abnormalities in LONSURF‑treated patients vs placebo-treated patients with refractory mCRC, respectively, were anemia (77% vs 33%), neutropenia (67% vs 1%), and thrombocytopenia (42% vs 8%).

Please see full Prescribing Information.